Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06994767 · ClinicalTrials.gov registry record · NA
Speech-derived Digital Biomarkers Study
A NA study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- NA
- Development phase
- 150
- Enrollment target
NCT06994767 is a NA study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 150 participants.
The verdict
NCT06994767, a NA study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
Study Summary
The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.
Interventions
- OTHER The Canary Application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2026-01-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06994767
The ClinicalTrials.gov registry entry for NCT06994767 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which The Canary Application is the first listed.
NCT06994767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06994767 about?
NCT06994767 is a clinical study titled "Speech-derived Digital Biomarkers Study". The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.
What is the current status of trial NCT06994767?
This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2025-05-19. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06994767?
The interventions under investigation include: The Canary Application (OTHER).
Who is sponsoring clinical trial NCT06994767?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.